Successful perioperative prophylaxis with susoctocog alfa in a patient with acquired haemophilia A: A case study.
作者信息
Buczma Anna, Baran Beata, Korwin Magdalena, Odnoczko Edyta, Windyga Jerzy
机构信息
Department of Hemostasis Disorders and Internal Medicine, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Laboratory of Hemostasis and Metabolic Diseases, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
出版信息
Haemophilia. 2022 Mar;28(2):e39-e41. doi: 10.1111/hae.14468. Epub 2021 Dec 8.
PMID:34878208
Abstract
摘要
相似文献
1
Successful perioperative prophylaxis with susoctocog alfa in a patient with acquired haemophilia A: A case study.苏托凝血因子α对获得性血友病A患者进行围手术期成功预防：一项病例研究。
Haemophilia. 2022 Mar;28(2):e39-e41. doi: 10.1111/hae.14468. Epub 2021 Dec 8.
2
Susoctocog Alfa: A Review in Acquired Haemophilia A.苏萨托考格阿尔法：获得性血友病 A 的研究综述。
Drugs. 2016 May;76(7):815-21. doi: 10.1007/s40265-016-0576-1.
3
Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial.在既往接受过治疗的重度甲型血友病患者中，使用重组人凝血因子VIII（诺易®）进行出血预防的长期安全性和有效性模式：Guardian（™）2扩展试验的中期结果
Haemophilia. 2015 Sep;21(5):e436-9. doi: 10.1111/hae.12737. Epub 2015 Jun 8.
4
Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A.一项使用重组人凝血因子VIII（turoctocog alfa）预防和治疗重度A型血友病患者出血的大型跨国扩展试验（监护人（™）2）的中期结果。
Haemophilia. 2016 Sep;22(5):e445-9. doi: 10.1111/hae.12990. Epub 2016 Jun 13.
5
Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A.蔗糖配方的重组人凝血因子VIII：用于A型血友病患者的综述。
Drugs. 2008;68(6):839-53. doi: 10.2165/00003495-200868060-00007.
6
Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: Final results from the guardian 2 extension trial.特奥罗科戈阿尔法预防和治疗重型 A 型血友病出血发作的长期安全性和有效性：守护者 2 扩展试验的最终结果。
Haemophilia. 2018 Nov;24(6):e391-e394. doi: 10.1111/hae.13617. Epub 2018 Nov 6.
7
A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.英国血友病中心医生组织指南，经英国血液学标准委员会批准：预防使用凝血因子 VIII 浓缩物治疗严重血友病 A 儿童和成人的指南。
Br J Haematol. 2010 May;149(4):498-507. doi: 10.1111/j.1365-2141.2010.08139.x. Epub 2010 Mar 11.
8
Temporarily successful eradication therapy in acquired haemophilia with high inhibitor titer: a case report with a new protocol.高抑制剂滴度获得性血友病的临时成功根除疗法：一份采用新方案的病例报告
Thromb Haemost. 2008 Jul;100(1):149-50. doi: 10.1160/TH07-06-0422.
9
On the treatment of hemorrhage in patients with hemophilia and associated inhibitors.
Transfusion. 2001 Dec;41(12):1628-9. doi: 10.1046/j.1537-2995.2001.41121628.x.
10
Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis.重新审视预防：新型因子和非因子疗法对预防的潜在影响。
Haemophilia. 2018 Nov;24(6):845-848. doi: 10.1111/hae.13558. Epub 2018 Jul 10.
引用本文的文献
1
Surgery and Prophylaxis with Susoctocog-Alfa in Acquired Hemophilia: Case Series and Literature Review.使用重组凝血因子IX（苏苏妥凝血因子α）治疗获得性血友病的手术及预防：病例系列与文献综述
J Clin Med. 2023 Jul 10;12(14):4590. doi: 10.3390/jcm12144590.
2
Analytical Performance of Different Laboratory Methods for Measuring Susoctocog-Alfa.不同实验室方法测定重组人凝血因子VIII的分析性能
Diagnostics (Basel). 2022 Aug 18;12(8):1999. doi: 10.3390/diagnostics12081999.
Zotero 插件